---
title: "Can-Fite BioPharma Falls 9% After Hours as Japan Approves Obesity Drug Patent"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291015546.md"
description: "Can-Fite BioPharma (CANF) drops 9% to $2.50 in after-hours, hitting record low despite Japan patent nod for obesity treatment."
datetime: "2026-06-26T23:43:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291015546.md)
  - [en](https://longbridge.com/en/news/291015546.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291015546.md)
generator: "portal-rs"
---

# Can-Fite BioPharma Falls 9% After Hours as Japan Approves Obesity Drug Patent

Can-Fite BioPharma（CANF.US）盘后跌**9.09%**，现报**2.5**美元。该股常规交易时段跌**6.46%**，盘后进一步走低触及纪录新低。消息面上，公司近日获日本专利局批准 Namodenoson 抗肥胖技术专利，覆盖 A3 腺苷受体激动剂用于减脂和治疗肥胖，但市场反应冷淡。

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [Can-Fite BioPharma Cuts Warrant Exercise Price to Secure $4 Million Inducement Financing](https://longbridge.com/en/news/297945371.md)
- [Can-Fite reports longer-than-expected survival in Phase III Namodenoson liver cancer trial](https://longbridge.com/en/news/297773746.md)
- [Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds | CANF Stock News](https://longbridge.com/en/news/297791360.md)
- [Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer](https://longbridge.com/en/news/296095129.md)
- [Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance](https://longbridge.com/en/news/295654944.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**